Blinatumomab for the treatment of adult B-cell acute lymphoblastic leukemia: Toward a new era of targeted immunotherapy

Miguel J. Franquiz, Nicholas J. Short

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lympho-blasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Uncertainty remains regarding the optimal sequencing and combination of blinatumomab with cytotoxic chemotherapy and other emerging agents. The pharmacology and clinical data on blinatumomab for adult B-cell ALL, both as monotherapy and in combinations, will be reviewed herein.

Original languageEnglish (US)
Pages (from-to)23-34
Number of pages12
JournalBiologics: Targets and Therapy
Volume14
DOIs
StatePublished - 2020

Keywords

  • Acute lymphoblastic leukemia
  • Adult
  • B-cell leukemia
  • Bispecific antibodies
  • Blinatumomab
  • Precursor cell lymphoblastic leukemia-lymphoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Blinatumomab for the treatment of adult B-cell acute lymphoblastic leukemia: Toward a new era of targeted immunotherapy'. Together they form a unique fingerprint.

Cite this